Get the Stockscreener App
46.29
1.69%
-0.8266
Harrow Inc stock is traded at $46.29, with a volume of 213.67K.
It is down -1.69% in the last 24 hours and down -6.19% over the past month.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
See More
Previous Close:
$47.12
Open:
$47.31
24h Volume:
213.67K
Relative Volume:
0.36
Market Cap:
$1.71B
Revenue:
$154.15M
Net Income/Loss:
$-33.58M
P/E Ratio:
-48.22
EPS:
-0.96
Net Cash Flow:
$-20.74M
1W Performance:
-4.47%
1M Performance:
-6.19%
6M Performance:
+28.29%
1Y Performance:
+34.08%
1-Day Range:
$46.16
$47.80
1-Week Range:
$44.55
$50.16
52-Week Range:
$20.85
$54.85
Harrow Inc Stock (HROW) Company Profile
Name
Harrow Inc
Sector
Phone
615.733.4731
Address
1A BURTON HILLS BLVD, NASHVILLE, CA
Compare HROW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HROW
Harrow Inc
|
46.16 | 1.75B | 154.15M | -33.58M | -20.74M | -0.96 |
|
ZTS
Zoetis Inc
|
123.97 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.64 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Harrow Inc Stock (HROW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-25 | Initiated | BTIG Research | Buy |
| Jun-10-25 | Initiated | William Blair | Outperform |
| Feb-06-25 | Initiated | H.C. Wainwright | Buy |
| Dec-04-24 | Reiterated | B. Riley Securities | Buy |
| Apr-11-24 | Initiated | Craig Hallum | Buy |
| Sep-08-22 | Resumed | B. Riley Securities | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Sep-24-21 | Initiated | Aegis Capital | Buy |
| Jul-02-21 | Initiated | Ladenburg Thalmann | Buy |
View All
Harrow Inc Stock (HROW) Latest News
Harrow (NASDAQ:HROW) Shares Down 4.4%Time to Sell? - MarketBeat
Harrow Health (NASDAQ:HROW) Expanding Clinical Reach In Ophthalmology - Kalkine Media
Market Trends: Can Harrow Inc expand into new marketsJuly 2025 Drop Watch & AI Enhanced Execution Alerts - baoquankhu1.vn
Pharma News: Can Harrow Inc. be recession proofTrade Risk Assessment & Weekly High Return Stock Forecasts - baoquankhu1.vn
Investment Recap: Can OptimizeRx Corporation weather a recessionQuarterly Trade Review & Weekly Setup with ROI Potential - baoquankhu1.vn
Breakeven Is Near for Harrow, Inc. (NASDAQ:HROW) - Yahoo Finance
LJI Wealth Management LLC Makes New Investment in Harrow, Inc. $HROW - MarketBeat
Opaleye management sells $711,814 worth of Harrow shares - MSN
Harrow announces leadership changes, Andrew Boll to serve as President and CFO - MSN
Harrow, Inc. (NASDAQ:HROW) Could Be Less Than A Year Away From Profitability - 富途资讯
Here's What Could Help Harrow (HROW) Maintain Its Recent Price Strength - sharewise.com
Harrow, Inc. (HROW): A Bull Case Theory - Finviz
Zacks Research Upgrades Harrow (NASDAQ:HROW) to "Strong-Buy" - MarketBeat
Gap Down: Can Harrow Inc maintain sales growthBull Run & Safe Capital Allocation Plans - baoquankhu1.vn
Panic Selling: What are the future prospects of Harrow IncTrade Exit Summary & Real-Time Volume Analysis - baoquankhu1.vn
Harrow: Flirting With Missing 2025 Revised Guidance (NASDAQ:HROW) - Seeking Alpha
Value Recap: Will Harrow Inc benefit from geopolitical trendsWeekly Trend Summary & Weekly Momentum Stock Picks - baoquankhu1.vn
Responsive Playbooks and the HROW Inflection - Stock Traders Daily
Institution Moves: Is Harrow Inc stock attractive for ETFsTrade Analysis Summary & Low Drawdown Investment Strategies - moha.gov.vn
Harrow Stock (-8.3%): Major Holder Sale Near Highs Sparks Distribution - Trefis
Is Harrow Inc. stock a good choice for value investorsJuly 2025 Spike Watch & Technical Pattern Recognition Alerts - Улправда
Harrow (NASDAQ:HROW) Trading Down 6%Here's What Happened - MarketBeat
How Harrow Inc. stock compares to growth peers2025 Short Interest & Accurate Trade Setup Notifications - Улправда
Major Harrow Health Backer Quietly Unloads a Chunk of Shares - TipRanks
Why Harrow Inc. stock remains a top recommendationMarket Growth Summary & Daily Price Action Insights - Улправда
Will Harrow Inc. stock deliver shareholder value2025 Key Lessons & Daily Stock Momentum Reports - Улправда
Harrow Health stock hits 52-week high at 54.85 USD - Investing.com
Harrow Health stock hits 52-week high at 54.85 USD By Investing.com - Investing.com South Africa
Most Volatile Stocks in the US (January 2026) - Investing.com
Harrow, Inc. (HROW) Stock Analysis: Navigating a 28.88% Upside Potential Amidst Robust Revenue Growth - DirectorsTalk Interviews
Harrow (NASDAQ:HROW) Hits New 12-Month HighWhat's Next? - MarketBeat
HARROW INC (NASDAQ:HROW) Emerges as a High-Growth Momentum Stock with Strong Technical Setup - Chartmill
Calamos Advisors LLC Makes New $1.09 Million Investment in Harrow, Inc. $HROW - MarketBeat
Harrow (NASDAQ:HROW) Hits New 1-Year HighTime to Buy? - MarketBeat
Harrow Health stock hits 52-week high at 51.38 USD - Investing.com
Harrow Health stock hits 52-week high at 51.38 USD By Investing.com - Investing.com UK
Harrow, Inc. (NASDAQ:HROW) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Brookstone Capital Management Grows Stock Holdings in Harrow, Inc. $HROW - MarketBeat
Harrow, Inc. $HROW Shares Sold by Rice Hall James & Associates LLC - MarketBeat
Harrow (NASDAQ:HROW) Has A Somewhat Strained Balance Sheet - 富途牛牛
Squarepoint Ops LLC Has $640,000 Stock Holdings in Harrow, Inc. $HROW - MarketBeat
First Week of February 2026 Options Trading For Harrow (HROW) - Nasdaq
Is Harrow Inc. stock vulnerable to regulatory risksJuly 2025 PreEarnings & Daily Technical Stock Forecast Reports - bolumsonucanavari.com
Will Harrow Inc. stock gain from strong economyAnalyst Downgrade & Stepwise Trade Signal Guides - Улправда
What margin trends mean for Harrow Inc. stockQuarterly Portfolio Summary & Long-Term Capital Growth Strategies - DonanımHaber
Why Harrow Inc. stock appeals to dividend seekersJuly 2025 Intraday Action & Real-Time Volume Trigger Notifications - Улправда
Insider Buy: Can Harrow Inc. stock resist market sell offsRate Hike & Free Accurate Trade Setup Notifications - ulpravda.ru
Is Harrow Inc. stock attractive for income investorsMarket Performance Report & Consistent Growth Equity Picks - Улправда
CFO Boll Acquires 33,335 Of Harrow Inc [HROW] - TradingView — Track All Markets
Harrow (HROW) CEO Mark Baum exercises 180,000 stock options in company - Stock Titan
Harrow (NASDAQ:HROW) Trading Down 5.8%Should You Sell? - MarketBeat
Harrow Inc Stock (HROW) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harrow Inc Stock (HROW) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| BOLL ANDREW R. | PRESIDENT AND CFO |
Dec 12 '25 |
Option Exercise |
3.95 |
60,000 |
237,000 |
837,844 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Dec 12 '25 |
Option Exercise |
3.95 |
180,000 |
711,000 |
3,066,124 |
| BAUM MARK L | CHIEF EXECUTIVE OFFICER |
Jul 21 '25 |
Option Exercise |
7.87 |
600,000 |
4,722,000 |
3,199,462 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Sale |
30.80 |
15,000 |
462,033 |
90,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 09 '25 |
Sale |
30.37 |
15,204 |
461,794 |
105,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 03 '25 |
Sale |
30.04 |
3,000 |
90,116 |
122,000 |
| Opaleye Management Inc. | 10% Owner |
Jun 04 '25 |
Sale |
30.02 |
1,796 |
53,907 |
120,204 |
| Opaleye Management Inc. | 10% Owner |
May 12 '25 |
Sale |
25.90 |
10,000 |
258,959 |
130,000 |
| Opaleye Management Inc. | 10% Owner |
May 13 '25 |
Sale |
26.59 |
5,000 |
132,945 |
125,000 |
| BOLL ANDREW R. | Chief Financial Officer |
Apr 03 '25 |
Option Exercise |
0.00 |
346,500 |
0 |
914,589 |
3.43%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):